NexoBrid与标准治疗在烧伤患儿中疗效与安全性的开放标签随机对照试验
这项多中心开放标签随机对照试验纳入145例0-18岁深部热烧伤患儿,随机分入菠萝蛋白酶类酶性清创(BBD)组72例与标准治疗(SOC)清创组73例。BBD组完成清创的中位时间更短(1天 vs 6天,P<0.001),手术切除创面面积百分比更低(均值1.5% vs 48.1%,P<0.001),12个月改良温哥华瘢痕量表(MVSS)评分非劣效(3.8 vs 4.9,P<0.001),两组不良事件发生率相似,无重大安全性问题或死亡。
要点
- BBD组完成清创中位时间1天,SOC组6天,差异有统计学意义(P<0.001)。
- BBD组手术切除创面面积均值1.5%,SOC组48.1%,差异有统计学意义(P<0.001)。
- 12个月MVSS评分BBD组3.8、SOC组4.9,非劣效成立(P<0.001)。
核心结论
- BBD在儿童中被证实安全有效,与SOC清创方法相比可缩短完成清创时间、减少切除手术,且外观与功能结果非劣效。
研究设计与样本
- 多中心、开放标签、平行设计、随机对照试验,在欧洲、美国、以色列和印度的36个烧伤中心开展。
- 纳入0-18岁、深部热烧伤面积占总体表面积1-30%的患儿;2015年至2020年入组145例,BBD组72例、SOC组73例,末例患者于2021年4月完成12个月随访。
主要发现
- 完成清创的中位时间BBD组1天 vs SOC组6天,BBD组更低(P<0.001)。
- 手术切除创面面积百分比均值[SD]为BBD组1.5%[12.1%] vs SOC组48.1%[46.6%],BBD组更低(P<0.001)。
- 12个月MVSS评分均值[SD]为BBD组3.8[2.9] vs SOC组4.9[3.3],非劣效成立(P<0.001)。
- 不良事件发生率两组相似,试验期间无重大安全性问题或死亡。
关键数值与推荐
- 主要终点包括完成清创时间(优效性)、手术切除创面面积百分比(优效性)和盲法12个月随访采用MVSS评估外观与功能(非劣效性),三项主要终点均达到。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study evaluated the safety and efficacy of an enzymatic bromelain-based debridement (BBD) agent (NexoBrid®) in children with deep thermal burns. METHODS: We conducted a multicenter, open-label, parallel design, randomized controlled trial at 36 burn centers in Europe, US, Israel and India. Main eligibility criteria included children 0-18 years old, suffering from deep thermal burns covering 1-30 % of their total body surface area. Patients were randomized to either BBD or standard of care (SOC) eschar removal methods. Primary endpoints included time to complete eschar removal (superiority), percentage of wound area surgically excised (superiority) and blinded 12 months follow-up assessment of cosmesis and function using the Modified Vancouver Scar Scale (MVSS, non-inferiority). RESULTS: One hundred and forty-five children were enrolled between 2015 and 2020 (last patient completed 12-month follow-up on April 2021); 72 were randomized to BBD and 73 to SOC. All three primary endpoints of the study were met. The median time to complete eschar removal was significantly lower in the BBD arm (1 vs. 6 days, P < 0.001). The mean [SD] percentage of wound area surgically excised was also significantly lower in the BBD arm (1.5 % [12.1 %] vs. 48.1 % [46.6 %], P < 0.001). Mean [SD] 12-month MVSS scores were 3.8 [2.9] and 4.9 [3.3] in the BBD and SOC arms, respectively (non-inferiority demonstrated at P < 0.001). The incidence of adverse events was similar between the groups, and there were no significant safety issues or deaths during the trial. CONCLUSIONS: BBD was demonstrated to be safe and effective in children. Its use lead to a shorter time to complete eschar removal, a reduction in excisional surgery and non-inferior cosmesis and function results as compared to SOC eschar removal methods.
引用
- Shoham Y, Rosenberg L, Narayan RP, et al. Open label randomized controlled trial of the efficacy and safety of NexoBrid compared to standard of care in children with burns. Burns. 2025. PMID: 40117996. doi:10.1016/j.burns.2025.107417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。